Header Logo

Connection

DANIEL HAMSTRA to Middle Aged

Back to Details
This is a "connection" page, showing publications DANIEL HAMSTRA has written about Middle Aged.
DANIEL HAMSTRA
Connection Strength
1.159
Middle Aged
  1. Bowel Disorder Incidence and Rectal Spacer Use in Patients With Prostate Cancer Undergoing Radiotherapy. JAMA Netw Open. 2025 Mar 03; 8(3):e250491.
    View in: PubMed
    Score: 0.060
  2. Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Pract Radiat Oncol. 2020 May - Jun; 10(3):186-194.
    View in: PubMed
    Score: 0.042
  3. Double-blind placebo-controlled multicenter phase II trial to evaluate D-methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer. Head Neck. 2018 07; 40(7):1375-1388.
    View in: PubMed
    Score: 0.037
  4. Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy. Am J Clin Oncol. 2018 Jan; 41(1):6-12.
    View in: PubMed
    Score: 0.036
  5. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):40-47.
    View in: PubMed
    Score: 0.035
  6. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352.
    View in: PubMed
    Score: 0.035
  7. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of?a?Phase III Trial. Int J Radiat Oncol Biol Phys. 2017 04 01; 97(5):976-985.
    View in: PubMed
    Score: 0.034
  8. Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol. 2015 Oct; 38(5):465-71.
    View in: PubMed
    Score: 0.031
  9. Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol. 2015 Aug; 38(4):367-72.
    View in: PubMed
    Score: 0.031
  10. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiat Oncol. 2014 Nov 26; 9:245.
    View in: PubMed
    Score: 0.029
  11. Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15; 121(6):844-52.
    View in: PubMed
    Score: 0.029
  12. The impact of numeracy on verbatim knowledge of the longitudinal risk for prostate cancer recurrence following radiation therapy. Med Decis Making. 2015 01; 35(1):27-36.
    View in: PubMed
    Score: 0.029
  13. A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):422-9.
    View in: PubMed
    Score: 0.028
  14. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer. 2014 Apr 01; 120(7):1076-82.
    View in: PubMed
    Score: 0.028
  15. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):721-8.
    View in: PubMed
    Score: 0.026
  16. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):554-61.
    View in: PubMed
    Score: 0.026
  17. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):546-53.
    View in: PubMed
    Score: 0.026
  18. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2013 May 01; 86(1):64-71.
    View in: PubMed
    Score: 0.026
  19. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1246-53.
    View in: PubMed
    Score: 0.026
  20. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer. 2013 Feb 01; 119(3):681-90.
    View in: PubMed
    Score: 0.025
  21. The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer. Radiat Oncol. 2012 Aug 01; 7:127.
    View in: PubMed
    Score: 0.025
  22. Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer. 2012 Apr 15; 118(8):2059-68.
    View in: PubMed
    Score: 0.023
  23. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e361-7.
    View in: PubMed
    Score: 0.023
  24. The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse. Radiother Oncol. 2011 Dec; 101(3):513-20.
    View in: PubMed
    Score: 0.023
  25. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e335-44.
    View in: PubMed
    Score: 0.023
  26. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e351-60.
    View in: PubMed
    Score: 0.023
  27. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1293-301.
    View in: PubMed
    Score: 0.023
  28. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):e135-42.
    View in: PubMed
    Score: 0.023
  29. Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin Cancer Res. 2010 May 01; 16(9):2666-76.
    View in: PubMed
    Score: 0.021
  30. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008 Jul 10; 26(20):3387-94.
    View in: PubMed
    Score: 0.019
  31. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005 Nov 15; 102(46):16759-64.
    View in: PubMed
    Score: 0.016
  32. Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. JAMA Netw Open. 2024 Oct 01; 7(10):e2440747.
    View in: PubMed
    Score: 0.014
  33. Two Specialists, Two Recommendations: Discordance Between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations. Urology. 2022 11; 169:156-161.
    View in: PubMed
    Score: 0.012
  34. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. BJU Int. 2020 09; 126(3):367-372.
    View in: PubMed
    Score: 0.011
  35. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2019 01 20; 37(3):213-221.
    View in: PubMed
    Score: 0.010
  36. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018 06 14; 4(6):e180039.
    View in: PubMed
    Score: 0.009
  37. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386.
    View in: PubMed
    Score: 0.009
  38. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2018 01; 121(1):61-68.
    View in: PubMed
    Score: 0.009
  39. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017 09; 120(3):351-357.
    View in: PubMed
    Score: 0.009
  40. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):304-317.
    View in: PubMed
    Score: 0.009
  41. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2017 05 01; 123(9):1635-1642.
    View in: PubMed
    Score: 0.008
  42. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. Radiother Oncol. 2016 11; 121(2):193-198.
    View in: PubMed
    Score: 0.008
  43. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053.
    View in: PubMed
    Score: 0.008
  44. Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol. 2017 02; 197(2):376-384.
    View in: PubMed
    Score: 0.008
  45. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016 10; 34(10):430.e1-7.
    View in: PubMed
    Score: 0.008
  46. Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis. 2016 09; 19(3):292-7.
    View in: PubMed
    Score: 0.008
  47. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):173-80.
    View in: PubMed
    Score: 0.008
  48. Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):181-8.
    View in: PubMed
    Score: 0.008
  49. Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU Int. 2016 09; 118(3):372-8.
    View in: PubMed
    Score: 0.008
  50. Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Med Oncol. 2015 Nov; 32(11):249.
    View in: PubMed
    Score: 0.008
  51. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84.
    View in: PubMed
    Score: 0.008
  52. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015 Oct 01; 93(2):294-302.
    View in: PubMed
    Score: 0.008
  53. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol. 2016 Jan; 69(1):50-7.
    View in: PubMed
    Score: 0.008
  54. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):229-36.
    View in: PubMed
    Score: 0.008
  55. Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiat Oncol. 2013 Aug 21; 8:204.
    View in: PubMed
    Score: 0.007
  56. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):275-81.
    View in: PubMed
    Score: 0.007
  57. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):99-107.
    View in: PubMed
    Score: 0.007
  58. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol. 2013 Jul 08; 8:170.
    View in: PubMed
    Score: 0.007
  59. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer. 2013 Sep 15; 119(18):3287-94.
    View in: PubMed
    Score: 0.007
  60. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 01; 119(9):1729-35.
    View in: PubMed
    Score: 0.006
  61. Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer. Med Dosim. 2012; 37(3):240-4.
    View in: PubMed
    Score: 0.006
  62. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):940-6.
    View in: PubMed
    Score: 0.006
  63. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14.
    View in: PubMed
    Score: 0.006
  64. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res. 2011 Jul 15; 17(14):4751-60.
    View in: PubMed
    Score: 0.006
  65. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010 May 01; 28(13):2293-9.
    View in: PubMed
    Score: 0.005
  66. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res. 2006 Sep 01; 66(17):8912-7.
    View in: PubMed
    Score: 0.004
  67. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998 Mar 01; 101(5):1102-10.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.